Home
Resources
Publications
The BMI1 Inhibitor PTC-209 Is a Potential Compound to Halt Cellular Growth in Biliary Tract Cancer Cells

The BMI1 Inhibitor PTC-209 Is a Potential Compound to Halt Cellular Growth in Biliary Tract Cancer Cells

Christian Mayr, Andrej Wagner, Magdalena Loeffelberger, Daniela Bruckner, Martin Jakab, Frieder Berr, Pietro Di Fazio, Matthias Ocker, Daniel Neureiter, Martin Pichler, Tobias Kiesslich

Oncotarget. 2016 Jan 5;7(1):745-58.

PMID: 26623561

Abstract:

BMI1 is a core component of the polycomb repressive complex 1 (PRC1) and is up-regulated in biliary tract cancer (BTC), contributing to aggressive clinical features. In this study we investigated the cytotoxic effects of PTC-209, a recently developed inhibitor of BMI1, in BTC cells. PTC-209 reduced overall viability in BTC cell lines in a dose-dependent fashion (0.04 - 20 µM). Treatment with PTC-209 led to slightly enhanced caspase activity and stop of cell proliferation. Cell cycle analysis revealed that PTC-209 caused cell cycle arrest at the G1/S checkpoint. A comprehensive investigation of expression changes of cell cycle-related genes showed that PTC-209 caused significant down-regulation of cell cycle-promoting genes as well as of genes that contribute to DNA synthesis initiation and DNA repair, respectively. This was accompanied by significantly elevated mRNA levels of cell cycle inhibitors. In addition, PTC-209 reduced sphere formation and, in a cell line-dependent manner, aldehyde dehydrogease-1 positive cells. We conclude that PTC-209 might be a promising drug for future in vitro and in vivo studies in BTC.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP315704666	PTC-209		315704-66-6	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: